By admin 
As growth in Vertex’s cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year.
After collecting $2.65 billion in second-quarter revenues, representing a 6% uptick from last year’s second quarter, Vertex lifted its full-year sales guidance to a range of $10.65 billion to $10.85 billion. The new forecast adds $100 million on either end of the company’s prior guidance.
The new numbers reflect expectations for continued cystic fibrosis growth and Casgevy’s uptake in its approved indications and markets, the company said in a release.
After Casgevy’s approval in sickle cell disease in December and subsequent FDA nod in beta thalassemia in January, it’s still early days in the groundbreaking launch. But Vertex is steadily expanding its patient base and continues to predict a “potential multi-billion opportunity,” according to its earnings presentation (PDF).
So far, around 20 patients have begun their treatment journey with the cell collection process, Vertex reported.